ESC Premium Access

Specific reversal agent for FXa - Inhibitor treatment - What the study data reveals? .

Topic: Pharmacology and Pharmacotherapy
Sponsored by Portola Pharmaceutials Inc.

Congress Presentation

About the speaker

Doctor Alexander Thomas Cohen

Guy's and St Thomas' NHS Trust Hospitals, London (United Kingdom of Great Britain & Northern Ireland)
13 presentations
0 follower

4 more presentations in this session

Introduction and welcome

Speaker: Associate Professor E. Grove (Aarhus, DK)


DOAC-related bleeding: demographics, risk factors & guidelines .

Speaker: Professor J. Oldgren (Uppsala, SE)


From clinical evidence to patient management- How to reverse DOAC in clinical practice .

Speaker: Professor S. Middeldorp (Amsterdam, NL)


Plenary questions and discussion

Speaker: Professor E. Lindhoff-Last (DE) Associate Professor E. Grove (Aarhus, DK)


Access the full session

Paradigm shift in DOAC reversal - What are the current therapeutic options?

Speakers: Doctor A. Cohen, Associate Professor E. Grove, Professor J. Oldgren, Professor S. Middeldorp, Professor E. Lindhoff-Last...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb